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ABSTRACT
BACKGROUND AND OBJECTIVE:
In Chronic Kidney Disease there is a higher incidence cardiovascular events. 
Most of the patients with CKD succumb to cardiovascular disease even before they 
reach the end stage of renal disease. Hence all efforts should be given in earlier 
stages of CKD to prevent the development of cardiovascular complications.
LV diastolic dysfunction is found to antedate LVH and systolic dysfunction. 
It is not just associated with hemodynamic factors like anaemia and hypertension, 
but also with uraemia related non hemodynamic factors like secondary 
hyperparathyroidism, altered mineral metabolism, cardiotrophysin etc.
ECHO provides a simple non-invasive method to assess the left ventricular 
structure and function, which helps us in identifying those prone for cardiovascular 
complications at an earlier stage of CKD.
This study was done to find out the prevalence of LV dysfunction  and its 
correlation with eGFR in CKD patients.
METHODS:
50 hypertensive CKD patients and  50 normotensive CKD patients admitted 
to Government Rajaji Hospital between May 2013 to August 2014 were evaluated 
for the presence of  LV dysfunction and LVH and the results were compared with 
that of 50 age and sex matched individuals.
Patients with acute kidney injury, prior coronary artery disease, valvular 
heart disease, cardiomyopathy, diabetic individuals and CKD patients on renal 
replacement therapy or transplant patients were excluded from the study.
The CKD patients were divided into various stages of CKD based on their 
eGFR (calculated according to MDRD formula) and they were evaluated by 
ECHO. Those with an ejection fraction < 50% were considered to have systolic 
dysfuction. Diastolic dysfunction was calculated based on the E/A ratio. E/A ratio 
<0.8 was grade I, 0.8 – 1.5 was grade II and >2 was grade III diastolic dysfunction. 
This was compared with the ECHO findings of the controls. The collected data 
was analysed using various statistical methods.
RESULTS:
74% of CKD patients had LV diastolic dysfunction  (p <0.0001). Diastolic 
dysfunction was found to occur in 84% of the hypertensive CKD and in 64% of the 
normotensive CKD (p=0.02).
Comparing the CKD normotensives with the control group, 64%  among the 
normotensive CKD had diastolic dysfunction whereas only16% of controls had 
diastolic dysfunction (p<0.05).
There is a negative correlation between the eGFR and diastolic 
dysfunction.So as the eGFR falls, the diastolic dysfunction increases.
INTERPRETATION AND CONCLUSION:
Even in the absence of hypertension, LV diastolic dysfunction can occur in 
CKD. This emphasizes the need for correction of not just hemodynamic factors but 
also the uraemia related factors.
KEY WORDS:
Chronic Kidney Disease, Left ventricular diastolic dysfunction, ECHO, eGFR
INTRODUCTION
Chronic kidney disease (CKD) is a spectrum of pathophysiological 
process that is associated with dysfunction of kidney and a progressive 
decrease in Glomerular Filtration Rate (GFR). (1)
It refers to functional or structural abnormalities of kidneys for 
more than three months, irrespective of cause.
It is a global health concern. CKD has been the 12th leading cause 
of death, and the 17th leading cause of disability. CKD has a number of 
co-morbidities and hence is a disease with high mortality.(2)
An analysis of risk factors for development and progression of 
CKD is necessary in clinical practice.
The result of CKD is loss of kidney function which in the long run  
leads to kidney failure, decreased kidney function and its complications,  
development of cardiovascular disease and death.(3) Improving outcomes 
in CKD requires prevention, detection, evaluation, and management of 
other chronic diseases, such as hypertension, hypercholesterolemia , 
diabetes and obesity.
The number of CKD patients is on the rise. The prevalence rate of 
CKD in India is not available due to lack of adequate data recording. In 
community based studies, the prevalence rate of CKD is from 0.79% to 
1.4%. The studies were done to detect stage 3 CKD or worse. The exact 
prevalence is higher than the one reported. The end stage renal disease 
(ESRD) incidence is reported as 160 to 232 per million population and 
the projected ESRD prevalence rate was 785 to 870 per million 
population.(4)
Screening and Early Evaluation of Kidney disease (SEEK); a 
community based study which was done recently  reported a very high 
prevalence rate of CKD which is about 17.4%.(5) The Indian CKD registry 
was formed in the year 2005 with a target to serve as a comprehensive 
nationwide data warehouse for studying the different aspects of CKD. 
The data house has enrolled about 63,538 patients and 74% of the cases 
have CKD stage 4 and stage 5.
The prevalence of End Stage Renal Disease (4) (ESRD) and the 
patients who are on renal replacement therapy has increased since last 2 
decades. Only 20% of ESRD patients are on Renal Replacement Therapy 
(RRT). It is estimated that 1,00,000 new patients of ESRD undergo renal 
replacement programs every year in India. 
The most common cause for CKD in India is Diabetes. It accounts 
for about 30 to 40% of patients. With the increasing number of diabetic 
patients there is a parallel increase in the incidence of CKD. In India the 
number of patients with diabetes is now about 41 million and is on the 
rise. Most of the patients develop diabetic nephropathy and land up in 
ESRD.
In Chronic Kidney Disease there is a higher incidence of 
cardiovascular events. Cardiovascular disease is one of the prime causes 
of morbidity and mortality in all the stage of CKD. Most of the patients 
with CKD develop cardiovascular disease before reaching ESRD. The 
CKD registry (6) has shown that  patients with CKD stage 4 have a high 
incidence of cardiovascular complications. Most of the patients die before 
they have ESRD. Patients in early stages of CKD are also found to have a 
high cardiovascular morbidity. Hence we should look into the prevention 
of cardiovascular complications.
A large cohort study of patients with CKD stages 2 to 4 showed 
that death was seen more often than progression to kidney failure in all 
stages of CKD. There was a high baseline prevalence of cardiovascular 
disease in the patients who died, compared to those who survived, which 
suggests that cardiovascular disease accounted for a huge proportion of 
the deaths. Hence, most patients in the earlier stages of CKD do not 
progress to kidney failure because of the mortality caused due to 
cardiovascular disease. Cardiovascular disease has been seen as a major 
“competing outcome or risk” of kidney failure. (3)
The cardiovascular manifestation in CKD includes: (13)
 Ischemic heart disease – myocardial infarction and angina 
 Left ventricular hypertrophy 
 Heart failure : LV diastolic and systolic dysfunction and 
 Dilated cardiomyopathy.
Heart and kidney are linked to each other in the hemodynamic and 
regulatory functions. There are multiple communications among the two 
organs like Sympathetic Nervous System, Anti Diuretic Hormone, Renin 
Angiotensin Aldosterone System and natriuretic peptides.(8) National 
Kidney Foundation formed a Task Force which considered Coronary 
Artery Disease (CAD) and LVH as the target conditions, recommended 
for decreasing cardiovascular mortality in ESRD.(9)
LVH is associated with both systolic and diastolic 
dysfunction. LVH associated with systolic dysfunction is expressed by 
decreased mid wall systolic fractional shortening and decreased ejection 
fraction. These findings show us that mild reduction in the renal perfusion 
which is caused by the slightly impaired LV systolic function, is 
associated with pathological, highly pulsatile perfusion in the 
microvasculature of the kidney. This might be the mechanism through 
which a progressive reduction of renal function takes place in patients 
with pre-existing renal damage. This renal insufficiency produced, 
adversely affects the function of the heart, which produces  a vicious 
cycle where the renal failure further impairs cardiac performance.
Diastolic dysfunction is associated with higher incidence of 
episodes  of  intradialytic hypotension and higher peri-operative death 
from pulmonary oedema at the time of renal transplantation. It is 
significant to recognize and correct the cardiovascular complications and 
risk factors before the commencement of dialysis.
Echocardiography will provide us with a very simple and non-
invasive assessment of the structure and function of the heart. It also 
helps us to identify the people who are at greater risk. Strategies to 
prevent the development and progression of LV dysfunction at an early 
stage may prove more effective.
AIMS AND OBJECTIVES:
1. To assess the prevalence of Left Ventricular (systolic and/ or 
diastolic) dysfunction in patients with CKD.
2. To evaluate the correlation between Left Ventricular 
dysfunction and eGFR in CKD patients
3. To compare the Left Ventricular dysfunction in hypertensive 
and normotensive CKD patients.
REVIEW OF LITERATURE
NORMAL ANATOMY AND PHYSIOLOGY OF KIDNEY
EMBRYOLOGY OF KIDNEY:
The kidney is one of the most highly differentiated organs in the 
body (10) They develop from the intermediate mesoderm under the timed 
and sequential control of genes. The excretory tubules (nephrons) develop 
from the metanephric blastema. The collecting part arises from the 
ureteric bud, which arises from the lower part of mesonephric duct. The 
ureteric bud grows cranially towards the metanephric blastema, and 
becomes dilated to form an ampulla. Ampulla undergoes division to form 
the major calyces, then minor calyces and finally the collecting tubules. 
(11)
GROSS ANATOMY:
Kidneys are a pair of excretory retroperitoneal organs, situated on 
each side of the vertebral column. It consists of two poles, extending from 
T12 to L3. The left kidney is at a lower level than the right. The 
approximate size of each kidney is 11 cm long, 5 cm wide and 3 cm in 
thickness. The weight of a single kidney is about 125 to 170 grams.   
Each kidney is surrounded by a fibrous capsule with perirenal pad of fat. 
Renal vessels, renal pelvis, lymphatics and nerve plexus enter through the 
hilum.   Kidney consists of an outer cortex and an inner medulla.  Cortex 
contains all the glomeruli and portions of the tubules, whereas the 
medulla is made of renal pyramids and renal columns. Minor calyx arises 
from the pyramids and joins to form the major calyces which form the 
renal pelvis. (10)
THE NEPHRON:
Nephrons are the functional units of kidney. Kidney contains 
approximately about 1.2 million nephrons. The nephron consists of 
malphigian or renal corpuscle (Bowman’s capsule and the glomerulus), 
the site at which blood is filtered and a renal tubule (the proximal tubule, 
thin and thick ascending limb, distal tubule and collecting ducts) from 
which solutes are reabsorbed. (10)
Glomerulus (Renal corpuscle): 
 It is a network of capillaries lined by endothelial cells, central 
mesangial cells, visceral epithelial cells and its basement 
membrane, parietal layer of Bowman’s capsule with its basement 
membrane.
 Visceral epithelium becomes continuous with the parietal 
epithelium at the vascular pole. Here the afferent arteriole enters 
and efferent arteriole exits. (10)
 It also helps in the production of an ultrafiltrate of plasma
Tubules:
 Continues from Bowman space and consists of proximal loop of 
Henle and distal tubule.
 The proximal convoluted tubule is lined by cuboidal cells which 
aids in the absorption of solutes.
 Loop of  Henle is made of a thin descending limb and a thick 
ascending limb, extending into cortex. The thick end of ascending 
limb reaches the glomerulus of the nephron and nestles between its 
afferent and efferent arterioles. Specialised cells at the end form the 
macula densa, particularly close to the afferent arteriole.(12)
 The macula densa, the neighboring lacis cells, and the renin-
secreting juxtaglomerular cells which are present in the afferent 
arteriole form the juxtaglomerular apparatus (12)
 Distal convoluted tubules coalesce to form the collecting ducts. 
The epithelium of collecting duct has principal (P cells) and 
intercalated (I cells). P cells are involved in Na+ reabsorption and 
vasopressin stimulated water reabsorption. The I cells are 
concerned with acid secretion and HCO3- secretion.(12)
VASCULAR SUPPLY OF KIDNEY:
Kidney is supplied by a single renal artery, a direct branch from 
abdominal aorta. Renal artery enters the hilum and divides into an 
anterior and a posterior branch.
 Lobar arteries: these are 3 segmental arteries arising from the 
anterior branch and supply upper, middle and lower third of the 
anterior surface of the kidney. Posterior branch supplies posterior 
half. These are end arteries and no collateral circulation has been 
demonstrated.(10)
 Inter lobar arteries: arises from the lobar arteries runs between the 
renal columns and pyramids.
 Arcuate arteries: arises from the interlobar arteries.
 Interlobular arteries: arises from the arcuate arteries and forms the 
afferent arterioles.
FUNCTIONS OF THE KIDNEY: (11)
A. Maintain solute and water homeostasis.
B. Serves as an endocrine organ by producing erythropoietin, active 
form of vitamin D and renin.
C. Excretion of metabolic products.
D. Regulation of blood pressure and intraglomerular hemodynamics.
E. Regulation of acid bases.
F. Elimination of toxic substances from the body.
G. Involved in catabolism of small peptide hormones.
H. Regulation of extra cellular volume and osmolarity.
AGE RELATED CHANGES OF KIDNEY:
The kidney attains its full anatomical and functional maturity by the end 
of 3rddecade of life. From then on, involutive changes start. Up to 6th 
decade these changes are slow and after this a rapid progression occurs 
due to reduced renal perfusion. Despite this, under normal circumstances 
these changes do not show any signs of renal insufficiency. (10)
KIDNEY IN YOUNG ADULTS:
Anatomical characteristics:
During this period, there is full maturation of all renal structures. 
The cortico-medullary index (cortex: medulla) increases from 1.64:1 in 
the new born to 2.59:1 in adults. The kidneys reach their maximum size 
during this period. (10)
Functional characteristics:
The kidneys are fully functional in adults due to its complete 
maturation. The normal Glomerular Filtration Rate (GFR) at this period is 
120 to 130 ml/min/1.73m2. GFR decreases as age advances.(10)
KIDNEY IN THE ELDERLY:
Anatomical characteristics:
Age produces changes that are similar to those in chronic kidney 
diseases. There is a progressive loss of kidney mass. The weight of both 
the kidneys decreases to 110 – 120 gram as the age increases. The lost 
kidney mass is mainly in the cortex, characterised by a reduction in the 
number of functional nephrons, whereas medulla is relatively spared. 
There is an enlargement of the mesangial matrix, thickening of the 
basement membrane and hyalinised arterioles, with a gradual reduction in 
the renal corpuscles. With ageing, renal vasculature undergoes changes 
regardless of hypertension or other diseases. The renal arteries undergo 
sclerosis resulting in ischemic nephropathy.
Functional characteristics:
In normal healthy persons the age related changes develop slowly. 
Increase in vascular resistance in the afferent and efferent arterioles 
decreases renal blood flow. There is a progressive decrease in the 
intensity of glomerular filtration. The creatinine clearance decreases at an 
average of 0.83ml/min/m2 per year. However serum creatinine does not 
change as there is a progressive decline in the muscle mass. The sodium 
preserving capacity is lowered due to its insufficient intake and there is 
reduced reabsorption of sodium by the distal tubules  due to interstitial 
fibrosis. The renin-angiotensin-aldosterone system activity is reduced.
The concentrating and diluting capacity of kidney is also reduced.
ADAPTATION OF KIDNEYS TO NEPHRON LOSS
The kidney’s ability of maintaining constancy of the extracellular 
fluid volume and composition is usually well preserved till late in the 
course of CKD. When nephrons are lost through disease, the rest of the 
nephrons undergo physiological changes resulting in hypertrophy and 
hyperfunction, which compensates for the loss. Studies in patients with 
CKD showed that; if the GFR falls below a critical level, the disease 
leads to end stage; even when initial disease activity has been controlled. 
This mechanism for the disease progression of CKD has been based on 
the Bricker’s intact nephron hypothesis, which states that:
“As CKD progresses; the kidney function is maintained by a decreasing 
pool of hyperfunctioning nephrons rather than a relatively constant 
number of nephrons with decreasing function”. 
RENAL PROGRESSION: (13)
Renal progression is a term used to define primary nephron 
loss which produces a maladaptive deterioration in the remaining 
nephrons. Irrespective of injury in the glomeruli or tubulointerstitium, it 
follows a common pathway. The mechanisms involved are:
 Glomerular hypertension reduces the single nephron GFR and the 
associated proteinuria.
 Proteinuria produces accumulation of interstitial mononuclear 
cells.
 Activation of nephritogenic T lymphocytes produces interstitial 
nephritis.
 Epithelial – mesenchymal transition forming new interstitial 
fibroblasts.
 Fibrosis of adjacent capillaries and tubular nephrons results   in    
acellular scar.
ROLE OF ANGIOTENSIN II IN RENAL PROGRESSION:
Angiotensin hastens renal progression in CKD patients. Aldosterone 
increases the renal vascular resistance and glomerular capillary pressure 
which complements the detrimental effects of Angiotensin. It causes renal 
damage by:
 Efferent arteriolar vasoconstriction which increases the 
intraglomerular capillary pressure.
 By selectively altering the glomerular size it induces protein 
ultrafiltration.
 Podocyte function is altered by increasing intracellular calcium.
 Oxidative stress in the surrounding renal tissues.
TUBULAR FUNCTION IN CHRONIC RENAL FAILURE: 
The loss of functioning nephrons in chronic renal failure produces 
a persistent intraglomerular hypertension.
Glomerulotubular balance is maintained; inspite of loss of 
functioning nephrons, by which the remaining nephrons increases the 
single nephron glomerular filtration. To maintain the solute homeostasis 
the tubular function is altered in CKD. (14)
1. SODIUM:
The transport of sodium and its ability to maintain extracellular 
volume is well preserved till late in CKD. Sodium excretion is increased 
by decreasing its reabsorption in the Henle’s loop and distal nephrons. 
There is increased excretion of organic and inorganic anions, and 
increased expression of atrial natriuretic peptide . As the disease 
progresses, compensatory changes are lost resulting in sodium retention, 
expansion of intravascular volume, oedema and worsening hypertension. 
(14)
2. Potassium:
Hyperkalemia can occur when the compensatory functions of the 
tubules are lost.
1. Urinary dilution and concentration:
CKD patients lose their ability to concentrate or dilute the urine. So the 
urine specific gravity is fixed and the patients are prone for nocturia.
2.      Acid base regulation:
The solute load of the remaining nephrons is increased which produces 
impaired total body H+ excretion. The hydrogen ion pumps are lost with 
reduction in ammoniagenesis resulting in non-delta acidosis. In advanced 
stages, the ammoniagenesis is further decreased by elevated potassium 
resulting in type IV renal tubular acidosis.
3. Calcium and phosphate: 
Kidneys and intestines are the key regulators of calcium phosphate 
metabolism. In chronic renal failure the excretion of phosphate is reduced 
resulting in hyperphosphatemia. Calcium level is reduced by the 
following ways: 
1. Decreased absorption in the gut
          2. Decreased calcitriol formation
3. Increased serum phosphate
4. Increased parathyroid hormone release. 
CHRONIC KIDNEY DISEASE
Chronic kidney disease (CKD) includes a spectrum of different 
pathophysiologic processes associated with abnormal kidney function and 
a progressive decline in glomerular filtration rate (GFR).(2)
Chronic Renal Failure is a term used for the continuing significant 
irreversible reduction in nephron number and corresponds to CKD stages 
3 – 5. (12)
End-Stage Renal Disease (ESRD) is defined as a stage of CKD 
where toxins, electrolytes and fluids which are normally excreted by 
kidney are accumulated and it is responsible for uremic syndrome. Which 
ultimately leads to death of the patient unless a renal replacement therapy 
using dialysis or renal transplantation is done where, the toxins are 
removed. (12)
The kidney functions as biosynthetic, excretory and metabolic 
organs, necessary for maintaining normal physiology. Although daily 
dialysis can replace some kidney functions, it cannot replicate the normal 
biosynthetic and metabolic activities of the kidney. (12)
DEFINITION OF CHRONIC KIDNEY DISEASE:
The National Kidney Foundation’s (NKF) “Kidney Disease 
Outcomes Quality Initiative (KDOQI)” has proposed a definition and 
classification scheme of CKD.  The NKF guidelines define CKD on the 
basis of kidney damage and or reduced renal function. (2)
Glomerular filtration rate is calculated from serum creatinine and 
equations with the help of age, sex, race, and BMI. CKD can be classified 
based on the level of GFR . (1) Stages 1 and 2 are kidney damage, stages 3 
and 4 are decreased kidney function and stage 5 is kidney failure. (3)
CRITERIA: (2, 1, 13)
1. Kidney damage ≥ 3 months, either functional or structural 
abnormalities, with or without decreased GFR, are seen by the 
following manifested
 Pathological abnormalities or
 Markers of kidney damage
i. Urinary abnormalities (proteinuria).
ii. Imaging abnormalities. (Bilaterally 
shrunken kidneys)
iii. Blood abnormalities.
2. GFR <60 ml/min/1.73m2 for 3 months or longer and with or without 
kidney damage.  
CLASSIFICATION OF CKD:
STAGE GFR / ml / 1.73 m2 ACTION
0 >90 a Screening: CKD risk reduction
1 >90 b Diagnosis and treatment
 Slowing the progression of 
the disease
 Treatment of comorbidities
 CVD risk reduction
2 60 -89 Estimating progression
3 30 – 59 Treating complications
4 15 – 29 Prepare for kidney replacement
5 <15 Kidney replacement                     
     
a -  risk factors for CKD
b - demonstrated kidney damage – persistent  proteinuria, 
abnormal urine sediment,
abnormal blood and urine chemistry, 
abnormal imaging studies (13)
Staging of CKD was based on the estimated glomerular filtration rate 
(eGFR) and not on serum creatinine level. In stage 1 and stage 2 the GFR 
is normal or near normal, so the patient must have an accompanying 
structural or functional defect (eg, proteinuria, or abnormal imaging 
studies) to classify under it.
RISK FACTORS FOR CKD: (14)
Hypertension
Diabetes mellitus
Autoimmune disease
Older age
African ancestry – genetic – APOL 1 gene
Family history of renal disease
Previous episode of acute kidney injury
Proteinuria
Abnormal urine sediment
Structural abnormalities of the urinary tract
Nephrotoxins
Dyslipidemia
Smoking
PATHOPHYSIOLOGY OF CHRONIC KIDNEY DISEASE:
It’s divided into two causes
1) Initiating mechanism
2) Progressive mechanisms
 Initiating mechanisms – this is caused due to a specific 
etiology. For example genetically determined abnormalities in 
the renal integrity or its development, immune complex 
deposition and inflammation in certain types of 
glomerulonephritis, toxin exposure in interstitial nephritis etc
 Progressive mechanisms –this is caused due to the 
hyperfiltration and hypertrophy of the remaining viable 
nephrons due to decreased renal mass, irrespective of 
etiology. These responses were mediated by the cytokines and 
growth factors, vasoactive hormones, and transforming 
growth factor (TGFß). (13)
         The increased intra-renal renin activity contributes to both initial 
inciting event and also to the progressive mechanisms, finally leading on 
to the glomerular sclerosis and renal failure.
Risk Factors for Chronic kidney disease and its outcome (14)
Risk Factors Definition Examples
Susceptibility 
factors
Increase susceptibility 
to kidney damage
Older age
Family history of Chronic
reduction in kidney mass
low birth weight
kidney disease
Initiation factors Directly initiate kidney 
damage
Diabetes
high blood pressure
autoimmune diseases
urinary stones
lower urinary tract obstruction,
systemic infections
urinary tract infections
drug toxicity
Progression 
factors
Cause worsening 
kidney damage and 
faster decline in kidney 
function after initiation 
of kidney damage
poor glycemic control in diabetes
Higher level of proteinuria
smoking
systolic blood pressure
End-stage 
factors
Increase morbidity and 
mortality in kidney 
failure
Lower dialysis dose 
low serum albumin level
(Kt/V) temporary vascular access 
anemia
Examples of Epidemiologic Studies Involving Patients with Kidney 
Disease
Study 
Design Examples
Prospective 
cohorts
Population Based Cohorts 
Atherosclerosis Risk in Communities Study 
(ARIC)
Framingham Heart Study
Cardiovascular Health Study (CHS)
Multi-Ethnic Study of Atherosclerosis 
(MESA)
Health, Aging and Body Composition (Health 
ABC)
Coronary Artery Risk Development in Young 
Adults (CARDIA)
Cohorts of Patients with Kidney Disease 
Chronic Renal Insufficiency Cohort (CRIC)
Cardiovascular Risk in Birmingham (CRIB)
United States Renal Data System (USRDS)
Choices for Healthy Outcomes in Caring for 
End Stage Renal Disease (CHOICE)
Interventio
n trials
Trials in Patients with Kidney Disease 
Modification of Diet in Renal Disease Study 
(MDRD)
African American Study of Kidney Disease 
(AASK)
Study of Heart and Renal Protection (SHARP)
Prevention of Renal and Vascular Endstage 
Disease Intervention Trial (PREVEND IT)
The Microalbuminuria Captopril Study
GruppoItaliano di StudiEpidemiologici in 
Nefrologia (GISEN)
Study 
Design Examples
Deutsche Diabetes DialyseStudie (4D)
Reduction of Endpoints in NIDDM with the 
Angiotensin II Antagonist Losartan (RENAAL)
Irbesartan in Diabetic Nephropathy Trial 
(IDNT)
Hemodialysis Study (HEMO)
The Ramipril Efficacy In Nephropathy (REIN)
Post Hoc Analysis of Trials in Populations with CVD 
or CVD Risk Factors 
Heart Outcomes Prevention Evaluation Trial 
(HOPE)
Cholesterol and Recurrent Events Trial (CARE)
Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT)
CAUSES OF CHRONIC KIDNEY DISEASE:
Diabetic glomerulosclerosis
Hypertensive nephrosclerosis
Glomerular 
Diseases
Systemic lupus erythematosus.
Amyloidosis, light chain disease.
Glomerulonephritis
Wegener’s granulomatosis
Tubulointerstitial
Diseases
Obstructive nephropathy (stones, benign 
prostatic hypertrophy).
Analgesic nephropathy.
Myeloma kidney.
Reflux nephropathy.
Vascular 
Diseases
Atheroembolic renal disease 
Vasculitis.
Scleroderma.
Reno vascular renal failure
Cystic 
Diseases
Medullary cystic kidney disease 
ADPKD.
CLINICAL PRESENATION:
Usually the patients are asymptomatic in the early stages of CKD. 
Hypertension and proteinuria are the most common features of CKD and 
are present in all stages of the disease. Uraemia leads to disruption in the 
function of all organ systems. Most common complications include 
anaemia, decreased appetite, and abnormalities in potassium, sodium, 
water and acid-base homeostasis, abnormalities in phosphorus, calcium 
and mineral regulating hormone.(13)
PATHOPHYSIOLOGY AND BIOCHEMISTRY OF UREMIA:
1. Consequent to accumulation of toxins that are normally excreted:
Even though urea and creatinine measures the excretory capacity of 
kidney, it is not the accumulation of these toxins that are responsible for 
the uremic symptoms. The toxins that are implicated in uremic syndrome 
include: hydrophobic, protein bound, water soluble, charged and 
uncharged molecules. Additional nitrogenous excretory products include 
urates, hippurates, guanidino compounds, polyamines, products of 
nucleic acid metabolism, myoinositol, benzoates, indoles and phenols. 
Compounds called middle molecules (molecular mass of 500 – 1500 Da) 
also contribute to morbidity and mortality. (13)
2. Consequent to loss of other renal functions:
Suppression of metabolic and endocrine functions results in anemia, 
malnutrition, abnormal metabolism of protein, carbohydrates and fats. 
FGF 23, PTH, insulin, glucagon, Vitamin D, sex hormones all change 
with renal failure. It occurs due to abnormal retention, decreased 
degradation or abnormal regulation. (13)
3. Progressive systemic inflammation and its vascular and 
nutritional consequences:
 Elevated CRP and acute phase reactants
 Negative acute phase reactants- albumin and fetuin decline.
So, the inflammation associated with CKD is important in 
malnutrition  inflammation-atherosclerosis/calcification syndrome.
The clinical presentation depends on the organ system involved, the 
manifestations include:
1. Fluid, electrolyte and acid-base disorders:
Sodium and water homeostasis:
In the early stages of CKD, the total body content of sodium and water is 
increased. Dietary intake of sodium exceeds the urinary excretion 
resulting in sodium retention and extra cellular (ECF) volume expansion. 
Thus resulting in hypertension.  Hyponatremia is not commonly seen in 
CKD patients, if it is present, it will respond to water restriction. Some 
patients may have impaired renal conservation of sodium and water. (13)
Potassium   homeostasis:
Hyperkalemia in CKD may be due to the following mechanisms:  
A. Increased dietary potassium intake.
          B.  Protein catabolism.
C.  Haemolysis, haemorrhage
          D.  Transfusion of stored blood and
          E.   Metabolic acidosis. 
F. Drugs – ACE inhibitors, ARBs, spironolactone, potassium 
sparing diuretics (amiloride, triamterene, eplerenone).
Hyporeninemic hypoaldosteronism, obstructive uropathy and 
sickle cell nephropathy may cause disruption of potassium secretory 
mechanism out of proportion to decline in GFR.
Hypokalemia is not common in CKD. It may occur in reduced 
dietary intake, excessive diuretic therapy, gastrointestinal losses, primary 
potassium wasting conditions – Fanconis syndrome, Renal Tubular 
Acidosis
Metabolic acidosis:
Commonly seen in patients with advanced CKD. The combination 
of hyperkalemia and hyperchloremic metabolic acidosis is often present. 
Non anion gap acidosis occurs in the early stages of CKD but in later 
stages as the disease progresses anion gap acidosis ensues.  Treatment of 
hyperkalemia increases the renal ammonia production; improve the renal 
production of bicarbonate thereby improving the metabolic acidosis.  (13)
Disorders of calcium and phosphate metabolism:
2. Bone manifestations of CKD:
Due to high bone turn over - secondary hyperparathyroidism produces 
Osteitis fibrosa cystica and low bone turn over produces            
adyanamic bone disease and osteomalacia. Reduced GFR (< 60 ml/min) 
leads to reduced excretion of phosphate - retained phosphate stimulates 
PTH- secondary hyperparathyroidism. PTH is by itself a uremic toxin.(13)
Fibroblast growth factor 23(FGF-23) is a phosphatonin that promotes the 
renal phosphate excretion. Studies have shown that high levels of FGF-23 
are an independent risk factor for left ventricular hypertrophy. Adynamic 
bone disease is most common in diabetics and elderly patients.  It is also 
associated with cardiac and vascular calcification. Osteomalacia is caused 
by vitamin D deficiency, metabolic acidosis. Renal osteodystrophy results 
from secondary hyperparathyroidism. (13)
Hyperphosphatemia and hypercalcemia causes increased vascular 
calcification of the media of coronary arteries and heart valves and 
increased cardiovascular mortality. (13)
Calciphylaxis (calcific uremic arteriolopathy) due to vascular and soft 
tissue calcification can occur in advanced CKD.
3 Neuromuscular abnormalities:
It results in peripheral neuropathy, autonomic neuropathy and 
myopathy. These abnormalities are due to the nitrogenous metabolites 
and middle molecules. In the early stages patients present with 
disturbances in the memory, concentration and sleep. Neuromuscular 
irritability, including hiccups, cramps, and fasciculations or twitching of 
muscles are seen in later stages. Asterixis, myoclonus, seizures and coma 
may occur in advanced untreated cases. (13)
             Peripheral neuropathy occurs from stage 4 of CKD and its 
evidence without any other cause is a firm indication for renal 
replacement therapy. Sensory nerves, lower extremities, distal parts are 
more involved than the motor, upper extremities and proximal part. 
‘Restless leg syndrome’ is a common manifestation.
4. Gastrointestinal and nutritional manifestations:
Uremic fetor can lead to dysgeusia. Other manifestations include 
gastritis, peptic ulcer disease, and mucosal ulcerations resulting in 
abdominal pain, nausea, vomiting and GI bleeding. Constipation is 
common in CKD and is worsened by calcium and iron supplements.
Protein energy malnutrition due to low protein and calorie intake is 
common in advanced stages. Metabolic acidosis and activation of 
inflammatory cytokines promotes protein catabolism. All the patients 
should be assessed for malnutrition from stage 3 of CKD. (13)
5.   Endocrine – metabolic manifestations:
Glucose metabolism is often impaired in CKD. Plasma insulin 
levels are elevated in most of the uremic patients as the kidneys fail to 
remove it. Due to the diminished degradation of insulin, insulin and 
hypoglycaemic agents require dose reduction.
In women with CKD, oestrogen levels are low. Menstrual 
abnormalities and infertility are common. Pregnancy may hasten the 
progression of the disease. Spontaneous abortions and miscarriages are 
common. Males have reduced plasma testosterone levels, sexual 
dysfunction and oligospermia. (13)
6. Dermatologic manifestations:
Pruritus is the most common and devastating complication of 
CKD. Hyper pigmentation of the skin due to the deposition of pigmented 
metabolites (urochromes) can occur. Nephrogenic fibrosing dermopathy 
occurs in patients exposed to gadolinium contrast. The                           
condition is characterised by progressive subcutaneous induration of arms 
and legs. (13)
7. Hematologic abnormalities:
Abnormal haemostasis:
Prolonged bleeding time
Decreased activity of platelet factor 3
Impaired prothrombin consumption
Abnormal platelet adhesion and aggregation
Thrombophilia occurs due to nephrotic range proteinuria, which 
results in hypoalbuminemia and renal loss of anticoagulant factors. (13)
ANAEMIA AND CHRONIC KIDNEY DISEASE
          Anaemia is most common in CKD patients and the cause for 
anaemia is multifactorial. Even though considered as normocytic 
normochromic due to erythropoietin deficiency, other factors like iron 
deficiency contributes a major proportion and this is worsened in patients 
on dialysis.
           Anaemia develops earlier in CKD patients with diabetes and it is 
more severe than with non-diabetic patients. The degree of anaemia 
reflects the severity of disease.
         Based on KDOQI guidelines, anaemia in CKD is defined as 
haemoglobin less than 12 gm/dl for men & postmenopausal women and 
11 gm/dl in premenopausal women.
         In general anaemia becomes more frequent as renal function 
declines, becoming almost universal in ESRD. Studies have demonstrated 
correlation of anaemia with progression of renal failure. A randomized 
cohort study RENAAL (Reduction of Endpoints in NIDDM with the 
Angiotensin II Antagonist Losartan) reports that for every 1g/dl decrease 
in haemoglobin, the risk of developing renal failure increases by 11%.
ETIOLOGY OF ANAEMIA IN CKD: 
1) Relative erythropoietin deficiency.
2) Iron deficiency (absolute/functional).
3) Decreased RBC survival.
4) Reduced dietary intake and absorption.
5) Bleeding diathesis.
6) Urinary loss of transferrin as a part of proteinuria leading to 
impaired iron transport.
CONTRIBUTORY FACTORS:
 Uremic toxins.
 Immunosuppressive drugs.
 Aluminium toxicity.
 Secondary hyperparathyroidism and bone marrow fibrosis.
 Folate and vitamin B12 deficiency.
 Associated HIV/HCV infections.
 Chronic inflammation and release of inflammatory cytokines.
 Haemoglobinopathy.
 Co-morbid conditions like hypo/hyperthyroidism, pregnancy, auto-
immune diseases, HIV diseases.
MANIFESTATIONS OF ANEMIA:
 Decreased quality of life, fatigue and diminished exercise tolerance
 Decreased mental acuity and cognitive functions.
 Decreased tissue oxygen delivery and utilization, increased cardiac 
output.
 Left ventricular dilatation and hypertrophy – Heart failure
 Angina/myocardial infarction
 Impaired immune response.
 Growth retardation in children
An association between modest decline in hemoglobin level and 
progressive left ventricular growth has been shown in the patients who 
have early renal insufficiency (15). There is decrease in left ventricular 
dimensions and an improvement in exercise capacity and cognitive 
functions due to partial correction of anemia.
HYPERTENSION AND CHRONIC KIDNEY DISEASE
Hypertension is a universal disease in all CKD patients and it is 
often manifested as an early sign of the disease. Hypertension is seen 
early in the course of CKD and is associated with left ventricular 
hypertrophy and accelerated progression of CKD to end stage renal
disease. Hypertension can lead to the early development of cardiovascular 
disease in CKD. Cardiovascular disease is one   of the main cause of 
increased morbidity and mortality. Thus we have to identify them at an 
earlier stage. 
Hypertension in CKD patients is due to an: (8)
 Expanded extracellular volume and a diminished sodium excretion. 
 Activation of renin –angiotensin– aldosterone system (RAAS) and 
the activation of sympathetic nervous system.
 Endothelial dysfunction
 Large artery stiffening
Patients with hypertension frequently have elevated serum uric acid 
levels and this may result in vascular damage contributing further to the 
development of hypertension in CKD.
Several prospective trials, like Multiple Risk Factor Intervention 
Trial (MRFIT)(16) and the systolic hypertension in elderly program, have 
shown a strong association between hypertension and rate of decline in 
kidney function and development of kidney failure. Analysis of National 
Health and Nutrition Evaluation Survey (NHANES) III data suggests that 
adequate BP control is achieved in only 11% of patients of CKD. More 
recent analysis of NHANES IV indicates that only 37% of hypertensive 
patients with CKD have BP controlled to a level of less than 130/80 mm 
Hg.
Risk factors for uncontrolled hypertension in CKD:
 Age more than 60
 Presence of albuminuria 
 Associated other comorbid illness like diabetes, coronary artery 
disease and cerebrovascular accident.
Documentation of BP is important in the assessment of CKD because 
this is strongly associated with kidney disease progression and 
cardiovascular mortality. Treatment of hypertension in CKD should 
include specification of target blood pressure levels, non pharmacological 
therapies and specific anti-hypertensive agents. 
Antihypertensive drugs reduce the albuminuria even in 
normotensive diabetic patients. Degree of blood pressure control appears 
to be an important factor in controlling the rate of progression of CKD.
The absence of hypertension in CKD may be due to: (13)
• Salt losing nephropathy – reflux nephropathy
o interstitial nephropathies
o post obstructive uropathy
o medullary cystic disease  
o acute phase of acute tubular necrosis
• Anti-hypertensive therapy
• Volume depletion
• Poor left ventricular function
Low blood pressure actually carries a worse prognosis. This along with 
reduced body mass index and hypolipidemia shows advanced 
malnutrition – inflammation state.
CARDIOVASCULAR DISEASE AND CKD:
Cardiovascular disease is the most common cause of mortality in 
all stages of CKD. Age adjusted cardiovascular mortality is about 30 
times higher in ESRD than in normal populations and more in dialysis 
patients. The risk is more in younger individuals with CKD. Most of the 
patients with CKD succumb to the cardiovascular disease even before 
they reach the end stage of renal disease. Hence all efforts of care should 
be given in the earlier stages of CKD to prevent the development of 
cardiovascular complications. (17)
Potential Mechanisms for Increased Cardiovascular Disease Risk in 
Chronic kidney disease (17)
1. Chronic kidney disease is associated with an increase in 
prevalence of cardiovascular disease risk factors and these 
cardiovascular disease risk factors promote development and 
progression of CKD.
2. Cardiovascular disease is a risk factor for CKD.
3. Chronic kidney disease is an independent risk factor for 
cardiovascular disease.
The clinical consequences of cardiac disease in CKD are 
cardiomyopathy, ischemic vascular disease, left ventricular hypertrophy, 
myocardial ischemia and cardiac failure, valvular lesions (due to dystro
phic calcification of mitral and aortic valves). (18, 19, 20)
CARDIOVASCULAR DISEASE AND STAGE OF CKD:
Presentation with cardiovascular disease is influenced by the duration, 
severity and type of renal disease. LVH is already present in earlier stages 
of CKD. As the disease progresses;  geometry of heart changes from 
concentric hypertrophy with normal LV volume; to eccentric hypertrophy 
with LV dilatation. Eventually LV growth and a decrease in myocardial 
contractility contribute to elevated LV pressures for a given volume, thus 
predisposing to heart failure. (21)
Manifestations of Cardiovascular Disease in CKD and  Risk Factors
Pathology
Traditional Risk 
Factors Non-traditional Risk Factors
Cardiomyopathy Older age Albuminuria
Hypertension Reduced glomerular filtration 
rate
Valvular disease Anemia
Dyslipidemia Inflammation
Smoking Arteriosclerosis
Diabetes Extracellular fluid volume 
overload
Abnormal calcium/phosphate 
metabolism
Atherosclerosis Older age Albuminuria
Male gender Reduced glomerular filtration 
rate
Hypertension Anemia
Diabetes Inflammation
Dyslipidemia Oxidative stress
Smoking Endothelial dysfunction
Physical inactivity Homocysteine
LVH Lipoprotein (a)
Malnutrition
Thrombogenic factors
Sympathetic activity
Insulin resistance/metabolic 
syndrome
Arteriosclerosis Older age Albuminuria
Male gender Reduced glomerular filtration 
rate
Pathology
Traditional Risk 
Factors Non-traditional Risk Factors
Smoking Endothelial dysfunction
Hypertension Abnormal calcium/phosphate 
metabolism
Diabetes Metabolic syndrome
Dyslipidemia

PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE IN 
CKD
Heart failure and Atherosclerosis are more common in CKD 
patients thereby increasing the cardiovascular related mortality. 
Cardiovascular disease accelerates the progression of CKD and vice 
versa. In addition, CKD patients usually present with atypical symptoms 
making the diagnosis difficult.
Cardiomyopathy may present as an enlarged, dilated left ventricle 
with or without systolic dysfunction, or as a hypertrophic ventricle with 
normal left ventricular volume and diastolic dysfunction. Left ventricular 
disease is more common in CKD patients and is already present in about 
85% patients of the patient starting on dialysis. Microvascular disease is 
also more common in CKD. Intramyocardial arterial wall thickening is 
the consistent finding independent of hypertension. It interferes with the 
perfusion reserve of the myocardium. There is also reduction in the 
capillary density interfering with myocardial blood and oxygen supply. 
Besides the anticipated accelerated atherosclerotic changes in the aorta, 
peripheral arteries and veins, calcification of the arterial media especially 
in the aorta leading to aortic stiffness, is an independent cardiovascular 
mortality.
The inflammatory state associated with CKD causes elevation of 
acute phase reactants due to the release of inflammatory cytokines like C-
reactive protein. There is an accelerated vascular occlusive disease in the 
presence of inflammation and the associated low levels of Feutin with 
hyperphosphatemia permits more rapid vascular calcification. (13)  
Thus, evaluation of a CKD patient should be properly investigated 
for the associated cardiovascular risk factors.
ISCHEMIC HEART DISEASE
Ischemic heart disease most results from atherosclerosis of the 
coronary arteries. Factors like hypertension, diabetes, and dyslipidemia 
accelerates atherosclerosis in CKD patients. Uremic state provides the 
hemodynamic, humoral, and metabolic abnormalities that induces 
endothelial cell activation and injury.
Coronary reserve is reduced in CKD caused because of marked left 
ventricular hypertrophy and microvascular disease. The episodes of 
recurrent hypotension and hypovolemia in haemodialysis patients may 
further aggravate coronary ischemia. Nitric oxide is reduced because of 
the elevated Asymmetric Di Methyl-Arginine (ADMA) augmenting the 
coronary ischemia. ADMA is the competitive inhibitor of nitric oxide 
synthase and is emerging as the strongest predictor of cardiovascular risk 
factor in ESRD. (21, 22)
LEFT VENTRICULAR HYPERTROPHY AND CKD (23)
It is an adaptive remodelling process, which compensates for the 
increased work load with the aim of minimising ventricular wall stress. 
 Pressure overload caused by increased afterload as in hypertension, 
arteriosclerosis, or aortic stenosis creates greater intracavitary 
pressure during ventricular contraction. This is achieved by 
arraying contractile proteins in parallel. As a result there is an 
increase in the wall thickness of interventricular septum and LV 
free (or “posterior” wall) and cavity volume remains normal. So 
that relative to the LV end diastolic diameter, wall thickness is 
increased. This is called as concentric hypertrophy. This leads to 
fall in diastolic compliance and there is a great risk of myocardial 
ischemia, even when there is no coronary artery disease. (22)
 In diseases like anemia, extracellular volume overload, and 
arteriovenous fistulas which causes volume overload, there is 
lengthening of contractile units this can lead into increase in the 
systolic stroke volume as described by Starling’s law. Left 
ventricular dilatation produces increased wall tension, increased 
oxygen requirements and myocyte damage. Therefore decrease 
wall tension is brought about by wall thickening, left ventricular 
dilatation and ventricular hypertrophy as secondary adaptations. 
This produces eccentric hypertrophy. (22)
The underlying molecular mechanisms are hypertrophy, apoptosis, 
and fibrosis that are influenced by growth factors, hormones, genetic 
factors and cytokines such as insulin like growth factor, angiotensin II, 
endothelin 1 and tumor necrosis factor alpha. Certain humoral factors like 
cardiac natriuretic peptide, troponin, homocysteine; asymmetric dimethyl 
arginine has also been implicated. (47)
Left ventricular (LV) pressure overload, LV volume overload and 
myocyte death in chronic uraemia (47)
Risk factors for left ventricular hypertrophy in patients with chronic 
renal insufficiency (47)
Not easily reversible Easily Reversible
Older age Diabetes 
mellitus Abnormally stiff  
large Arteries
Arteriovenous connections
Anaemia
Hypertension 
Extracellular fluid volume 
expansion
Uremic internal milieu
Abnormalities of calcium 
phosphate homeostasis
Eventually LV hypertrophy becomes maladaptive; there is a 
resultant energy deficit. The electrophysiological abnormalities and 
maintenance of systolic efficiency occurs at the expense of impaired 
diastolic filling. Arrhythmias can occur due to conduction abnormalities 
secondary to fibrosis and due to prolongation of action potential from 
slower reuptake of calcium by sarcoplasmic reticulum. This along with 
fibrosis and increased LV stiffness contributes to diastolic dysfunction.
CONGESTIVE HEART  FAILURE AND CKD:
The prevalence of heart failure increases with declining kidney 
function. It is the leading cause of mortality in CKD patients with higher 
mortality for diastolic than systolic failure.
Pathophysiology:
The mechanisms that causes LV failure in CKD 
 pressure overload (due to hypertension and vascular 
stiffness),
 volume overload, 
 CKD associated non hemodynamic factors
Catalytic iron dependent oxidative stress
Inappropriate activation of the renin-angiotensin system,
Inflammation
Stimulation of prohypertrophic and profibrogenic factors 
(transforming growth factor B , cardiotrophin-1, fibroblast growth factor-
23, galectin-3) (48)
Pathophysiology of cardiomyopathy and ischemic heart disease in 
chronic uraemia (47)
Imbalance between increased collagen synthesis and 
decreased collagen degradation causes myocardial fibrosis which is 
responsible for LV stiffness, disturbances in diastolic filling  and 
increased LV filling pressure which leads on to diastolic 
dysfunction.
The syndrome of heart failure is characterised by fatigue, effort 
intolerance and oedema. LVH, LV systolic and diastolic dysfunction can 
be diagnosed by Tissue Doppler Echocardiography imaging.
The current Kidney Disease Outcome Quality Initiative (KDOQI) 
guidelines recommend ECHO for all patients with stage 5 CKD, 1- 3 
months after renal replacement therapy and 3 years thereafter, regardless 
of symptoms. However earlier screening and closer follow up may 
increase the prognostic value.
Prevention and treatment:
Prevention plays an important role in the progression of CKD. BP 
control and modification of the risk factors which causes CHF can help us 
to stop the further progression of the disease. Dietary salt restriction 
forms the mainstay of counselling. Intensive diuretic therapy is needed to 
treat the CHF as compared to CHF in a patient with normal kidney 
function. ACE Inhibitors, new direct renin inhibitors, ARBs and 
mineralocorticoid receptor blockers are required for management of CHF 
in CKD. Recent studies suggest that these of carvedilol and bisoprolol in 
CKD with CHF. (48)
Other management strategies include 
- Correction of anaemia (Hb> 10g/dl) reduces LVH. Intravenous 
iron and erythropoiesis stimulating agents shows us that it 
improves exercise tolerance but they have shown that there is no 
survival benefit.
- Minimising vascular calcification by control of calcium and 
phosphorus concentration – using non calcium containing 
phosphate binders , avoiding excessive low or high parathyroid 
hormone concentrations and adequate vitamin D status
Premature cardiovascular disease plays a significant role in the 
morbidity and mortality in CKD. ECHO is an excellent non-invasive 
method which can help us with the wall dimensions, details of anatomy 
of cardiac cavity and wall movement.
SYSTOLIC DYSFUNCTION
LVH is associated with both systolic and diastolic dysfunction. 
LVH is associated with systolic dysfunction expressed by decreased mid 
wall systolic fractional shortening and decreased ejection fraction. When 
there is a mild reduction in renal perfusion induced by slightly impaired 
LV systolic dysfunction, which is accompanied with pathological, highly 
pulsatile perfusion in kidney microvasculature might be mechanisms 
through which a progressive reduction of renal function takes place in 
patients with pre-existing renal damage. This renal insufficiency 
produced, affects cardiac function, producing a vicious cycle were the 
CKD can further decrease the cardiac function.
DIASTOLIC DYSFUNCTION
Diastolic dysfunction refers to a mechanical failure of the heart’s 
chambers to fill properly with blood during the diastole phase of the 
cardiac cycle. This is caused by inadequate relaxation of the ventricles 
during diastole. Here the systolic function or the mechanical contraction 
of the heart is normal. Impairment of the diastolic phase can lead to 
inadequate filling of the left ventricle leads to a decrease in the amount of 
blood that is pumped out of the heart to oxygenate. In addition, if the 
ventricle does not fill with blood adequately, blood is drawn back into the 
atrium and eventually into the lungs, raising the pressure gradient of 
blood in the pulmonary vessels. This mismatched pressure gradient 
causes fluid or transudate to flow from these vessels into the lung alveoli, 
thereby causing pulmonary oedema.
The LV diastolic dysfunction appears to be the initial left 
ventricular dysfunction and might even preceed left ventricular 
hypertrophy. Diastolic heart function is influenced by numerous factors
such as myocardial relaxation and compliance, transvalvular pressure 
gradient, heart rate, atrial contraction, preload, respiratory variant, the 
restraint of pericardium and thoracic wall, as well as arrhythmias and 
valve incompetence. The abnormal ventricular filling in uraemia results 
increased LV stiffness caused by intramyocardial fibrosis and associated 
delayed relaxation. By virtue of an increase in LV stiffness, small 
changes in LV volume results in large changes in LV pressures, thus 
predisposing to symptomatic pulmonary oedema. Sometimes volume 
depletion can result in a large fall in LV pressure with symptomatic 
hypotension and hemodynamic instability.
Hypertension, anaemia and alteration in fluid and electrolyte 
balance are identified as major determinants of LVH in CKD. However 
beyond hemodynamic factors, inappropriate activation of RAAS, 
inflammation, oxidative stress, collagen and muscle growth plays a role. 
Impairment of diastolic dysfunction can occur early, even in the absence 
of LVH. So early detection of LV dysfunction in CKD could lead to an 
improvement in CV outcomes in CKD. (23)
Although patients with CKD have high traditional risk factors, this 
isn’t fully responsible for CV mortality (27). Other factors such as:
 secondary hyperparathyroidism ,
 changes in mineral metabolism  
 Impaired clearance of some growth factors. The carboxy 
terminal peptide of collagen type 1 (PICP) or   
cardiotrophin- 1 (CT-1) were elevated in CKD patients than 
those with normal function.
 osteoblasts and osteophytes secretes FGF 23, which maintains 
serum phosphate concentrations in CKD by stimulating 
phosphorus excretion and decreasing dietary phosphorus 
absorption through inhibition of 1, 25OH vitamin D 
synthesis. (39, 40, 41, 42). This increased concentrations of FGF 
23 in CKD patients induces fibrosis. This increased 
myocardial fibrosis has a central role in diastolic 
dysfunction. 
 There is also a role for inflammation in diastolic dysfunction 
as demonstrated by increased CRP. (50)
Grading of diastolic dysfunction:
 Grade I –Inversion of ratio of peak early to peak atrial velocity –
curve, with reduced early ventricular filling, due to reduced 
ventricular relaxation
This is the mildest form of diastolic heart failure. Patients are 
usually asymptomatic. Grade 1 = impaired relaxation pattern              
with normal filling pressure. Grade 1a = impaired relaxation pattern with 
increased filling pressure 
 Grade II –Pseudonormalisation of E/A flow pattern, due to 
increased atrial and ventricular filling pressures and decreased 
ventricular relaxation.
 Grade III – This is a severe form of diastolic dysfunction 
characterized by restrictive filling of the heart that leads to 
symptoms of advanced heart failure. When the patient is asked to 
perform the Valsalva maneuver during echocardiography, the 
diastolic abnormalities seem to reverse. This grade III dysfunction 
is therefore also called reversible restrictive diastolic dysfunction.
 Grade IV – This is also a severe form diastolic dysfunction 
characterized by restrictive filling. However, at this stage, the 
abnormalities are not reversible and grade IV diastolic dysfunction 
is also called “fixed restrictive diastolic dysfunction”.
Pathophysiology of cardiovascular dysfunction in CKD
Approach to treatment of left ventricular disorders and cardiac failure in patients 
with chronic kidney disease. (17)
VALVULAR CALCIFICATION(13)
 Valvular lesions in CKD are acquired and are due to dystrophic 
calcification. Aortic and mitral valves (annulus and leaflets) are 
commonly involved. Aortic valve stenosis evolves from valve 
sclerosis and is associated with increased cardiovascular mortality.
 Risk factors associated are age, duration of dialysis, 
hyperphosphatemia, and elevated calcium phosphate product.(13)
PERICARDIAL DISEASE:
Pericarditis is very common. It is an absolute indication for dialysis. 
Sometimes it is associated with pericardial effusion
GLOMERULAR FILTRATION RATE (7)
GFR is the primary metric for kidney function and its direct 
measurement involves administration of inulin or iothalamate a 
radioactive isotope that can be filtered at the glomerulus but neither 
secreted nor absorbed.
Serum creatinine is a useful marker to estimate the level of GFR. 
However serum creatinine is not an ideal marker of GFR, because it is 
both filtered at the glomerulus and secreted by the proximal tubules. GFR 
is related directly to the urine creatinine and inversely to the serum 
creatinine (Ucr / Up). The estimated GFR using the following methods 
are superior for the assessment of renal function:
1) MDRD (Modification of Diet in Renal Disease study) equation  :
eGFR(ml / min / 1.73 m2) = 186.3 × (Plasma creatinine) -1.154× (age) -0.203
x  0.742  if female
x  1.21  if African American
2) Cockcroft-Gault equation :
This equation was used to predict creatinine clearance (CrCl), but has 
been used to estimate GFR
CrCl or eGFR = (140-age) ( Body weight in Kg)  x 0.85 if female
        (Serum creatinine) x (72)
 CKD – EPI eGFR  = 141 x min (S. creatinine / k, 1)a x max 
MDRD equation has poorer accuracy when GFR > 60 ml / min / 1.73 m2
The chronic use of glucocorticoids, gradual loss of muscle mass 
due to chronic illness or malnutrition can mask significant changes in 
GFR.
PROTEINURIA:
Proteinuria is the most important early indicator of kidney damage. 
The gold standard test for evaluation of albuminuria is the measurement 
of 24 hour urine protein. The measurement of albumin to creatinine ratio 
in spot first void urine is a better method in practice.
ASSESSMENT OF PROTEIURIA
Urine collection 
method
Normal Micro 
albuminuria
Albuminuria or 
clinical 
proteinuria
Total 
protein
24-hour urine 
protein
< 300 
mg/dl
-- >300 mg/dl
Spot urine 
protein/creatinine 
ratio
< 200 
mg/g
-- > 200 mg/g
Albumin 24-hour excretion < 30 
mg/day
30-300mg/day >300 mg/day
Spot albumin 
specific dipstick
<3 
mg/dl
>3 mg/dl --
Spot urine 
albumin/creatinine 
ratio
<17 
mg/g for 
men.
<25 
mg/g for 
women.
17-250 mg/g 
for men.
25-355 mg/g 
for women.
>250 mg/g for 
men.
>355 mg/g for 
women
ECHOCARDIOGRAPHY AND CKD
M mode and two dimensional echocardiography provides us with  
a non-invasive and cheap procedure to assess the left ventricular structure 
and function. They also help us in the imaging of valves and pericardium. 
Systolic dysfunction can be diagnosed by measuring ejection fraction or 
low fractional shortening. You can also use ECHO to look at the LVH 
and LV geometry. The degree of hypertrophy can calculated by 
measuring the LV mass index or increased thickness of LV wall.
Diastolic LV function can be measured by Doppler analysis when 
flow in the mitral valve during diastole.  When the mitral valve opens 
there is ventricular relaxation which leads to sudden increase in flow 
measured as E (‘early’) peak. This is followed later by increase in the A 
(‘atrial’) peak, which reflects the atrial contraction. By assuming that the 
atrial function is normal, the increased stiffness of the LV due to LVH as 
in CKD, leads to smaller E peak and a bigger A peak, expressed as 
decreased E/A ratio.
Dobutamine stress echocardiography can be used in CKD patients 
for screening for ischaemic heart disease. It can also be used to determine 
the systolic reserve in patients with impaired systolic function or valvular 
heart disease.
MATERIALS AND METHODS
STUDY POPULATION: 
     This study is to be conducted among 100 established CKD patients 
who are admitted in Govt. Rajaji Hospital, Madurai in the General 
Medicine and Nephrology Departments and 50 age and sex matched 
controls. Out of the 100 CKD patients, 50 will be hypertensive and 50 
will be normotensive CKD patients.
Cases were classified into different stages of Chronic Kidney 
Disease based on estimated Glomerular filtration rate (eGFR). eGFR was 
calculated using MDRD formula. 
MDRD (Modification of Diet Renal Disease study) equation  :
eGFR(ml / min / 1.73 m2) = 186.3 × (Plasma creatinine) -1.154× (age) -0.203
x 0.742 if female
INCLUSION CRITERIA:
 Age > 18 years, both sex, with established Chronic Kidney 
Disease
i.e.: Symptoms and signs of renal disease > 3 months
Proteinuria > 1g/dl
Ultrasonography showing kidney size < 8.5 cm
Reduced creatinine clearance (eGFR) pointing to CKD
 Those who have not received any forms of renal replacement 
therapy.
 50 hypertensive (BP > 140/90) and 50 normotensive CKD patients 
in whom the duration of CKD is matched.  
 50 sex and age matched healthy individuals as controls.
EXCLUSION CRITERIA:
 Age < 18 years and > 70 years
 Patients with Acute Kidney Injury
 Patients with history and clinical features suggestive of pre-
existing cardiac diseases like rheumatic valvular heart disease, 
congenital heart disease, coronary heart disease, cardiomyopathy 
and pericardial diseases.
 Patients on dialysis and kidney transplant patients
 Patients who are diabetic
ANTICIPATED OUTCOME:
1. There is LV dysfunction both systolic and or diastolic in CKD 
patients as compared to controls.
2. Diastolic dysfunction is first to appear in CKD patients and will 
be present in more number of patients as compared to systolic 
dysfunction.
3. Lower the eGFR more severe will be the LV dysfunction
4. CKD patients with hypertension and anemia will have more 
severe LV dysfunction.
DATA COLLECTION:
A previously designed proforma will be used to collect the 
demographic and clinical details of the patients and controls. A thorough 
clinical examination will be done. An ECG and an Ultrasound Abdomen 
will be taken. 
Blood investigations taken. Echocardiography will be taken 
according to the standard guidelines. All measurements were made  
following American Society of Echocardiography (ASE) 
recommendations.
 Patients with EF < 50% were accepted as having LV systolic 
dysfunction
 Diastolic dysfunction was graded according to the ratio of 
transmitral early (E) and late (A) flow velocities (E/A ratio)
E/A ratio   <0.8 – Grade1
0.8 – 1.5 – Grade 2
           >2 – Grade 3
LABORATARY INVESTIGATIONS:
                   Blood samples were collected from all participants to 
estimate Haemoglobin. Blood urea, and Serum creatinine. Urine sample 
will be analysed for albuminuria.
DATA ANALYSIS:
The final data was entered onto Microsoft excel sheet 2010 and 
statistical analysis was done using SPSS software. The statistical tools 
applied were median, mean, standard deviation , Pearson’s correlation 
and chi – square test coefficient. These results are considered very 
significant when the p value < 0.001 and significant if p value < 0.05
DESIGN OF STUDY:  Cross sectional analytical study.
PERIOD OF STUDY: May 2013 to August 2014
COLLABORATING DEPARTMENTS:
Department of General Medicine, 
Department of Nephrology, 
Department of Cardiology,
Department of Radiology, 
Department of Biochemistry.                           
ETHICAL CLEARANCE: Obtained
CONSENT :  Individual written and informed consent.
ANALYSIS :  Statistical analysis – Chi square, 
   Pearson’s correlation coefficient
CONFLICT OF INTEREST : NIL
FINANCIAL SUPPORT : NIL
OBSERVATION AND RESULTS
TABLE 1:  PARAMETERS OF PARTICIPANT GROUPS
CKD + HTN
(n=50)
CKD + NT
(n=50)
CONTROLS
(n=50)
Age 54.12±13.06 54.64±14.72 54.06±12.59
Sex : Male
         Female                     
35
15
35
15
35
15
BP (mm Hg)                  
Systolic
Diastolic
160±10.2
102±6.2
126±6.8
82±4.6
116±6.2
76±3.8
Body weight 52.96±9.92 51.82±11.37 56.52±11.73
BMI 21.95±4.22 21.68±3.96 22.85±4.5
eGFR 
(ml/min/1.73m2)
14.59±13 22.21±13.31 95.27±17.04
S.creatinine(mg/dl) 7.44±5.35 3.77±1.78 0.83±0.16
Hb% 7.39±2.40 7.72±1.56 12.85±2.02
LVEF 50.68±10.41 53.98±9.19 55.6±9.02
Diastolic dysfunction 1.75±0.75 1.57±0.89 0.81±0.28
TABLE 2    
AGE DISTRIBUTION OF THE STUDY POPULATION
Mean age (± S.D): 54.12±13.06 years, minimum: 32 years, maximum: 70  
years.
                  About 52% of study subjects were in the age group of 41-60 
years while 36% were aged 61-70 years.
12%
24%
28%
36%
Age distribution of study population
31-40 41-50 51-60 61-70
AGE GROUP CKD + HTN
(n = 50)
CKD + NT
(n= 50)
CONTROLS
(n = 50)
31-40 6 6 6
41-50 12 12 12
51-60 14 14 14
61-70 18 18 18
TABLE 3
AGE DISTRIBUTION BASED ON THE STAGE OF CKD
STAGES AGE 31-40 AGE 41-50 AGE 51-60 AGE 61-70
STAGE 3 2 7 5 5
STAGE 4 6 8 9 7
STAGE 5 4 10 14 23
  
              
As age advances, stage of CKD also increases. 
0
5
10
15
20
25
STAGE 3 STAGE 4 STAGE 5
AGE DISTRIBUTION BASED ON THE STAGE OF 
CKD
31-40
41-50
51-60
61-70
GENDER DISTRIBUTION
GENDER CKD + HTN
MALE
FEMALE
    
Majority of the study subjects were males (70%) while the remaining 
30% were females.
TABLE 4
(n = 50)
CKD + NT
(n = 50)
CONTROLS
(n = 50)
35 35
15 15
MALES
70%
FEMALES
30%
Gender distribution
35
15
TABLE 5
GENDER DISTRIBUTION BASED ON STAGE OF CKD (n = 100)
In all stages of CKD, males have a higher prevalence than females.
0
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35
Stage 3 Stage 4 Stage 5
Male
Female
GENDER DISTRIBUTION BASED ON STAGE OF CKD
STAGE MALE FEMALE
STAGE 3 17 2
STAGE 4 22 7
STAGE 5 31 20
TABLE 6
DISTRIBUTION OF STUDY GROUP ACCORDING TO STAGE 
OF CKD 
STAGE CKD + HTN
(n = 50)
CKD + NT
(n = 50)
3 5 14
4 15 15
5 30 21
Stage 5 CKD has a higher number of hypertensives (30%) 
5
15
30
14 15
21
0
5
10
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20
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35
Stage 3 Stage 4 Stage 5
CKD+HTN CKD+NT
TABLE 7
DISTRIBUTION OF STUDY POPULATION ACCORDING TO 
ECHOCARDIOGRAM
CKD+HTN
(n=50)
CKD + NT
(n=50)
CONTROLS
(n=50)
SYSTOLIC 
DYSFUNCTION(SD)
13(26%) 4(8%) 1(2%)
DIASTOLIC 
DYSFUNCTION(DD)
42(84%) 32(64%) 8(16%)
LVH 40(80%) 23(46%) 10(20%)
84% of CKD with hypertension had diastolic dysfunction, while only 
26% of the same group had systolic dysfunction. In CKD with 
normotension 64% had diastolic dysfunction, whereas only 8% had 
systolic dysfunction. 
0
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SD DD LVH
Distribution of study population 
according to ECHO
CKD+HTN
CKD+NT
CONTROLS
PREVALENCE OF 
DD PRESENT
CKD 
CONTROLS 
TOTAL
74% of CKD patients have diastolic dysfunction as compared to 16% in 
controls. This association was found to be
square test.
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TABLE 8
LV DIASTOLIC DYSFUNCTION IN CKD
DD ABSENT TOTAL
74 26 100
8 42
82 68 150
Chi square p value < 0.0001
extremely significant by Chi 
CONTROLS
50
DD PRESENT
DD ABSENT
COMPARISON OF DIASTOLIC DYSFUNCTION IN 
DD PRESENT
CKD + HTN 
CKD + NT
TOTAL
84% of CKD with hypertension have diastolic dysfunction as 
compared to 64% in CKD normontensives. This association was found to 
be statistically significant.
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TABLE 9
CKD + HTN AND CKD + NT
DD ABSENT TOTAL
42 8
32 18
64 26
Chi square p value = 0.022
CKD+NT
DD ABSENT
DD PRESENT
50
50
100
TABLE 10
COMPARISON OF DIASTOLIC DYSFUNCTION IN CKD + NT 
AS COMPARED TO CONTROLS
DD PRESENT DD ABSENT TOTAL
CKD + NT 32 18 50
CONTROLS 8 42 50
TOTAL 40 60 100
Chi square p value < 0.05
64% of CKD with normotension have diastolic dysfunction as compared 
to 16% in controls. This association was found to be statistically 
significant.
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TABLE 11
PREVALENCE OF SYSTOLIC DYSFUNCTION IN CKD
SD PRESENT SD ABSENT TOTAL
CKD + HTN 13 37 50
CKD + NT 4 46 50
CONTROLS 1 49 50
26% of CKD with hypertensives and 8% of CKD normotensives had 
systolic dysfunction. This was found to be statistically significant, but 
when CKD normotensives were compared with that of controls, this 
association was found to be not significant.
13
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4
37
43
46
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SD PRESENT SD ABSENT
PREVALENCE OF ANAEMIA IN STUDY
STAGE Hb <7 gm/dl
STAGE 3
STAGE 4
STAGE  5
There is a higher prevalence of anaemia as CKD progresses. Hb was 
found to be > 7 gm/dl in all CKD patients in stage 3 and <
CKD patients in stage 5. 
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TABLE 12
GROUP (n=100)
Hb 7-10 gm/dl Hb >10 gm/dl
0 17
5 24
28 22
7gm/dl in 28 
STAGE 4 STAGE  5
2
1
1
>10
7_10
<7
TABLE 13
DISTRIBUTION OF LVH (n = 70)
CKD + HTN CKD + NT CONTROLS
LVH 40 20 10
In patients with LVH 55% of them were CKD hypertensives compared to 
31% were CKD  normotensives.
55%31%
14%
LVH
HTN
NORMOTENSIVE
CONTROL
CORRELATION BETWEEN eGFR AND DIASTOLIC 
According to Pearson’s correlation coefficient; the correlation 
between eGFR and diastolic dysfunction was calculated and R value 
obtained was R= - 0.90682. This showed that there is a moderate negative 
correlation between   eGFR and diastolic dysfunction. That is as the 
eGFR decreases, the diastolic dysfunction increases.
TABLE 14
DYSFUNCTION
DISCUSSION
Various epidemiological studies show that a moderate reduction in 
kidney function is associated with increased cardiovascular risk, and that 
the level of kidney function is an independent predictor of cardiovascular 
outcome (24, 25, 26)
The main aim of the study was to demonstrate the prevalence of 
left ventricular dysfunction in CKD as compared to that of controls and 
its correlation with the eGFR. 
The association of various parameters like sex, age, BMI, LVH 
was also studied.
In this study, the study participants were divided into three groups. 
50 hypertensive CKD patients, 50 normotensive CKD patients and 50 
controls being age and sex matched.
It was observed that there was a declining trend in eGFR and Hb 
with the progression of renal failure, while there was an ascending trend 
with systolic and diastolic blood pressure and serum creatinine.
Age distribution in study population:
The mean age group of the study population was 54.12±13.06 
years.  The minimum age was 32 years and the maximum age was 70 
years. About 52% of study subjects were in the age group of 41 - 60 
years, while 36 % were aged between 61 – 70 years. Thus we have shown 
in our study that the prevalence of CKD is most prevalent in 4th – 6th 
decade. In India, CKD is reported within the mean age of 50 years. In 
SEEK study; CKD has a mean age group of 45 years.(5)
Sex distribution in study population:
In my study, 70 % of CKD patients were males, and 30% CKD 
patients were females. This shows that CKD is more common in males 
than in females.  This is in accordance to the SEEK study (5), where males 
showed a higher prevalence than females. The Indian CKD registry (6) 
show that the CKD male: female ratio was 70: 30. The age and gender 
distribution of the population in both the study and control groups were 
almost equal and were comparable.
Blood pressure in study population:
The mean systolic BP was 160±10.2 mm Hg in hypertensive group 
and 126±6.8 mm Hg in normotensive group. The mean diastolic BP was 
108±6.2 mm Hg in hypertensive and 82±4.6 mm Hg in normotensive 
group. The mean systolic BP in the controls was 116±2.9 mm Hg and 
mean diastolic BP was 75.5±3.8 mm Hg.
Anaemia in study population:
In this study, CKD patients had significant anaemia with mean 
haemoglobin of about 7.39±2.40 gm/dl in CKD hypertensive group, 
7.72±1.56 gm/dl in CKD normotensive group and 12.85±2.0 gm/dl in 
controls. There was not much of a difference between the CKD 
hypertensive and normotensive group; although a better haemoglobin 
value was expected in the normotensive patients.
Serum creatinine and eGFR values:
The average Serum creatinine values in CKD hypertensives, CKD 
normotensives and controls are 7.44±5.35, 3.77±1.7 and 0.83±0.16. The 
average eGFR values in CKD hypertensives, CKD normotensives and 
control groups are 14.59 ± 13, 22.21 ± 13.31 and 95.27 ± 17.04 mg/dl. 
This shows that CKD hypertensives have a very low eGFR as compared 
to that of controls.
Left ventricular Hypertrophy:
In my study 55% of patients with LVH were CKD hypertensives as 
compared to 31% were CKD normotensives. This is in accordance with 
the study done by Levin et al which showed that 70% of ESRD patients 
had LVH  (35) and Paoletti et al 74% had LVH (36)
LV systolic dysfunction:
26% of CKD with hypertensives and 8% of CKD normotensives 
had systolic dysfunction. This was found to be statistically significant, but 
when CKD normotensives were compared with that of controls, this 
association was found to be not significant. This is similar to the study 
conducted by Shah Harsh D et al, Raj et al and P. Dangri et al.(19) This 
suggests that LVEF is well maintained till late. This shows that when the 
ventricle is stressed by a haemodynamic overload, it first uses its 
compensatory mechanism to maintain normal performance. Its only when 
all these compensatory mechanisms have been maximally used that there 
is a decline in ejection phase indices.
LV diastolic dysfunction:
74% of CKD patients have diastolic dysfunction as compared to 
16% in controls. This association was found to be extremely significant 
by Chi square test. (p value <0.0001)
The average E/A ratio in CKD hypertensives were 1.75 ± 0.75. 
According to Virtenen et al, in Grade 5 CKD, the mean E/A ratio is1.5 ± 
0.5. (31).In my study, 84% of CKD with hypertension have diastolic 
dysfunction as compared to 64% in CKD normontensives. This 
association was found to be statistically significant. (p value = 0.02)
The average E/A ratio in CKD normotensives were 1.57 ± 0.89. 
64% of CKD with normotension have diastolic dysfunction as compared 
to 16% in controls. This association was found to be statistically 
significant. (p value <0.05)
It was found during the study that, among the control group 8 out 
of 50 has E/A ratio less than 1.These were people who were above 60 
years and here diastolic dysfunction was considered physiological.
This study shows that there is a statistically significant occurrence 
of diastolic dysfunction in CKD with normotensives as compared to that 
of control. This proves that it is not the hemodynamic risk factors such as 
hypertension and anaemia alone that contributes to LVH and LV 
dysfunction. The uraemia related risk factors also plays a role. So 
management should be aimed at not only hypertension and anaemia but 
also control of uraemia related risk factors.
LV diastolic dysfunction is frequent among CKD patients and may 
produce heart failure and mortality. It has been reported that in ESRD, 
diastolic dysfunction deteriorates in parallel with LVH. (43, 44) The 
negative outcome is stronger in patients with diastolic failure. (45)
Diastolic dysfunction in CKD may occur early even in the absence of 
LVH (46)
According to Pearson’s correlation coefficient; the correlation 
between eGFR and diastolic dysfunction was calculated and R value 
obtained was R= - 0.90682
This showed that there is a moderate negative correlation between 
eGFR and diastolic dysfunction. That is as the eGFR decreases, the 
diastolic dysfunction increases.
To conclude, patients with CKD have higher prevalence of 
diastolic and systolic dysfunction and the diastolic dysfunction antedates 
the systolic dysfunction. (50, 51, 52, 53, 54)
SUMMARY
The main aim of the study was to demonstrate the prevalence of 
left ventricular dysfunction in CKD as compared to that of controls and 
its correlation with the eGFR.
The mean age group of the study population was 54.12±13.06 
years. In my study, 70 % of CKD patients were males, and 30% CKD 
patients were females.
The mean systolic BP was 160±10.2 mm Hg in hypertensive group 
and 126±6.8 mm Hg in normotensive group. The mean diastolic BP was 
108±6.2 mm Hg in hypertensive and 82±4.6 mm Hg in normotensive 
group. The mean systolic BP in the controls was 116±2.9 mm Hg and 
mean diastolic BP was 75.5±3.8 mm Hg.
In this study, CKD patients had significant anaemia with mean 
haemoglobin of about 7.39±2.40 gm/dl in CKD hypertensive group, 
7.72±1.56 gm/dl in CKD normotensive group and 12.85±2.0 gm% in 
controls.
The average S. creatinine values in CKD hypertensives, CKD 
normotensives and controls are 7.44±5.35, 3.77±1.78 and 0.83±0.16 
mg/dl.
  The average eGFR values in CKD hypertensives, CKD 
normotensives and control groups are 14.59 ± 13, 22.21 ± 13.31 and 
95.27 ± 17.04 ml/min/1.73 m2.
In my study 80% of CKD hypertensives had LVH as compared to 
64% normotensives. 26% of CKD with hypertensives and 8% of CKD 
normotensives had systolic dysfunction.
74% of CKD patients have diastolic dysfunction as compared to 
16% in controls. This association was found to be extremely significant.
64% of CKD with normotension have diastolic dysfunction as compared 
to 16% in controls.
According to Pearson’s correlation coefficient; the correlation 
between eGFR and Diastolic dysfunction was calculated and R value 
obtained was R= - 0.90682. This showed that there is a moderate negative 
correlation between eGFR and diastolic dysfunction.
CONCLUSION
 Left ventricular diastolic dysfunction is more significantly 
associated with the decline in eGFR than systolic dysfunction in 
CKD patients. This is found to occur at an earlier stage of CKD , 
even without LVH. Thus diastolic dysfunction is a much better 
predictor for cardiovascular mortality.
 The lower the eGFR, the more severe the LV diastolic dysfunction.
 LV diastolic dysfunction is more, if there is associated 
hypertension and anaemia. So, early identification and treatment of 
above conditions can retard the cardiovascular morbidity and 
mortality.
 Even in the absence of hypertension, LV diastolic dysfunction can 
occur in CKD. This emphasises on the need for correction of non-
hemodynamic factors like secondary hyperparathyroidism, 
inflammation, oxidative stress, myocardial fibrosis, and altered 
mineral metabolism. Research should be focused on modalities that 
can intervene with the above factors in addition to the control of 
traditional hemodynamic factors.
 Echocardiography provides a simple, non-invasive investigation 
that can identify even asymptomatic patients at an earlier stage of 
CKD. So, earlier screening of CKD patients for LV diastolic 
dysfunction can be recommended.
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PROFORMA
PARTICULARS OF THE PATIENT :
Name:                                                                                                           Case No:
Age/ Sex:
Address:
Contact No:                                                                     
PRESENTING COMPLAINTS:
Breathlessness Chest pain
Oliguria                 Altered sensorium
Abdominal pain/ vomiting Others
Volume overload Easy fatigue ability
PAST HISTORY:
Duration of CKD:
Treatment details:
MEDICAL HISTORY:
Hypertension
Diabetes
Smoker/ Alcoholic
CLINICAL EXAMINATION:
Pallor : Pedal oedema:
Height : Weight: BMI:
Vitals:  BP                           MAP (Mean Arterial Pressure):                   
System Examination:
CVS:
RS:
Abdomen:
CNS:
INVESTIGATIONS:
Hb%
    Urine: Albumin Sugar Deposits
24 hour urinary protein:
RBS
Lipid profile:    S. cholesterol:  LDL: HDL: TG:
Blood Urea:
Serum creatinine:
MDRD (Modification of Diet Renal Disease study) equation  :
eGFR (ml / min / 1.73 m2) = 186.3 × (Plasma creatinine) -1.154× (age) -0.203
x 0.742 if female
ECG:
USG Abdomen: Right kidney size: Left kidney size:
ECHOCARDIOGRAPHY:
LVEF:
E/A ratio:
LVH: concentric eccentric:
MASTER CHART
S.NO NAME AGE SEX WEIGHT HEIGHT BMI S.CREATININE eGFR BP Hb DD LVEF LVH
1 Akbar 69 M 54 1.5 24 2.5 27.39704 134/88 7.6 _ 56 N
2 Alaguraja 58 M 59 1.47 27.30344 15.9 3.356021 200/140 3.9 2.3 54 C
3 Angulakshmi 68 F 55 1.52 23.8054 2.6 19.4867 154/92 9.6 _ 58 C
4 Aravind Raja 42 M 69 1.62 26.29172 0.8 112.8567 160/110 13 - 56 C
5 Arokyasamy 66 M 60 1.58 24.03461 15 3.496521 150/90 4.2 2.2 40 C
6 Arumugam 45 F 50 1.49 22.52151 2.2 25.6956 160/90 8 1.2 49 C
7 Arumugam 52 M 60 1.54 25.29938 1.5 52.31845 150/96 12.8 _ 53 C
8 Azhagar 57 M 56 1.63 21.0772 1.8 41.60886 132/82 9.1 0.7 54 N
9 Bagyalakshmi 65 F 54 1.54 22.76944 0.6 106.8092 130/80 11.8 - 63 N
10 Bagyam 69 F 42 1.56 17.25838 0.7 88.32573 100/70 11.5 - 54 N
11 Balamurugan 43 M 58 1.6 22.65625 0.9 98.04442 116/76 12.8 - 57 N
12 Balasubramani 47 M 56 1.57 22.71897 5.3 12.44408 100/60 8.6 _ 46 C
13 Baskaran 65 M 63 1.59 24.9199 1 79.83465 108/84 12.4 0.9 55 N
14 Bharani 63 M 58 1.54 24.45606 1 80.34276 148/98 14 - 52 N
15 Bose 62 M 56 1.56 23.01118 6.7 8.975673 116/84 6.3 2.3 58 N
16 Chandramohan 67 M 64 1.56 26.29849 0.8 102.6488 114/82 12.7 - 54 N
17 Chandran 35 M 42 1.57 17.03923 4.5 15.95731 118/88 7.1 1.8 50 C
18 Chidambaran 51 M 68 1.58 27.23922 1 83.8641 146/96 14 - 46 N
19 Chinnathambi 63 M 58 1.59 22.94213 1.6 46.70811 132/86 9.2 _ 61 N
20 Dhiraviam 42 M 48 1.59 18.98659 6.4 10.24145 142/92 8.3 1.9 56 C
21 Dinakaran 69 M 50 1.5 22.22222 0.9 89.06983 110/70 13.1 - 54 N
22 Eswari 65 F 48 1.49 21.62065 10 4.155233 150/90 5.9 2.2 52 C
23 Ganesh 44 M 42 1.59 16.61327 10.6 5.667467 160/110 5.4 2.2 39 C
24 Gnanasoundari 58 F 58 1.5 25.77778 4.7 10.16342 114/88 6.8 1.4 51 C
25 Gomathiammal 48 F 46 1.54 19.39619 0.6 113.5895 100/80 11 - 59 N
26 Gomathy 53 F 50 1.54 21.08281 3.2 16.13042 120/80 8.6 1.6 58 N
27 Gopal 43 M 56 1.58 22.4323 3.6 19.79911 140/100 9 1.3 45 C
28 Gowri 68 F 52 1.5 23.11111 7.9 5.404503 124/76 5 2.3 55 C
29 Gunaseelan 63 M 61 1.58 24.43519 0.9 90.72999 130/76 12.9 - 56 N
30 Gunasekhar 54 M 51 1.6 19.92188 3.7 18.31606 170/100 9.5 1.4 55 C
31 Guru 67 M 52 1.6 20.3125 2.4 28.89056 100/70 8 _ 52 C
32 Habidhulla 57 M 56 1.6 21.875 0.9 92.5922 110/80 13 - 56 N
33 James 37 M 45 1.58 18.02596 1.7 48.52101 120/80 7.9 _ 52 C
34 John Manoj 35 M 67 1.59 26.50212 0.9 102.2283 160/96 12.5 - 59 N
35 Kailarajan 44 M 66 1.55 27.47138 1 86.41556 160/100 13.5 - 53 C
36 Kaliammal 50 F 40 1.5 17.77778 2.3 23.89417 150/90 10.8 _ 58 N
37 Kalimuthu 60 M 59 1.59 23.33768 18.2 2.851844 160/80 3.6 2.4 52 C
38 Kannan 59 M 52 1.59 20.56881 2.6 27.03029 150/90 8.3 1.1 52 N
39 Karikalan 65 M 69 1.6 26.95313 0.9 90.1562 112/78 12.6 0.8 54 N
40 Kartheeshan 59 M 58 1.59 22.94213 1.7 44.13589 110/80 8.9 0.8 54 C
41 Karthikeyan 51 M 52 1.55 21.64412 3.6 19.12507 136/74 8.4 1.3 42 C
42 Karuppiah 48 M 45 1.49 20.26936 1.9 40.47988 116/84 7 0.6 60 N
43 Karuppusamy 38 M 45 1.6 17.57813 16.7 3.455429 200/120 6.1 2.3 41 C
44 Kesavan 43 M 62 1.58 24.83576 0.9 98.04442 160/100 14 - 53 N
45 Koothammal 55 F 53 1.5 23.55556 11.7 3.586218 170/110 4.6 2.3 46 C
46 Krishnamoorthy 49 M 53 1.63 19.94806 0.8 109.3798 94/66 14 - 58 N
47 Krishnan 67 M 54 1.58 21.63115 2 35.65587 126/76 8.9 _ 54 C
48 Kumar 64 M 72 1.59 28.47989 1 80.08632 160/100 12.4 0.7 57 C
49 Lakshmanan 69 M 55 1.53 23.49524 0.9 89.06983 160/100 14 - 52 C
50 Latha 36 F 46 1.45 21.87872 7 7.070404 110/70 5.4 2.4 59 N
51 Madasamy 56 M 50 1.57 20.2848 2.3 31.47 190/120 10 0.9 47 C
52 Mahalakshmi 52 F 49 1.58 19.62826 0.7 93.54594 146/96 12.8 - 64 N
53 Malasamy 63 M 58 1.61 22.37568 6.4 9.432244 150/108 6.3 1.9 54 C
54 Maniappan 45 M 54 1.58 21.63115 2 38.65646 120/80 9.4 _ 58 N
55 Manikalai 46 M 53 1.58 21.23057 4.3 15.90928 150/90 9 1.4 45 C
56 Maniratinam 52 M 60 1.58 24.03461 1 83.53417 146/94 12.8 - 52 N
57 Mariappan 42 M 51 1.59 20.17325 0.8 112.8567 120/90 12.8 - 65 N
58 Marimuthu 66 M 63 1.59 24.9199 0.8 102.9626 158/92 13.2 0.9 53 N
59 Mariyappan 61 M 50 1.59 19.7777 23 2.169487 170/110 3.2 2.5 62 C
60 Meenakshi 35 F 50 1.47 23.13851 3.2 17.54801 180/100 6.5 1.3 50 C
61 Mohammed Jinnah 45 M 56 1.58 22.4323 2.6 28.55824 140/92 9.6 1 65 N
62 Mohammed Naseer 36 M 49 1.47 22.67574 2.7 28.60814 110/76 8.2 1.1 57 N
63 Mookammal 62 F 48 1.56 19.72387 0.7 90.26473 150/94 12.2 - 51 N
64 Mookan 36 M 49 1.63 18.44255 6.4 10.567 90/60 7.6 _ 40 C
65 Moorthy 46 M 52 1.56 21.36752 1.9 40.83113 110/76 8 _ 59 N
66 Muniyandi 54 M 53 1.59 20.96436 1.9 39.52349 100/70 7.5 0.7 58 N
67 Muniyandi 68 M 65 1.6 25.39063 0.9 89.33419 140/96 14.5 0.8 52 N
68 Muniyappan 64 M 57 1.62 21.71925 2.5 27.81862 190/120 7.2 1.1 52 C
69 Murugesan 39 M 65 1.58 26.03749 0.9 100.0071 110/80 13.8 - 58 N
70 musthafa hameed 70 M 56 1.55 23.30905 10.7 5.102101 140/90 6.5 2.1 52 N
71 Muthu 47 M 57 1.53 24.34961 1.9 40.65326 116/88 9.3 _ 55 N
72 Mydeen 50 M 55 1.53 23.49524 10.1 5.838954 180/110 6.8 2.1 40 C
73 Nadiammal 58 F 56 1.54 23.61275 15.6 2.545512 160/100 5 2.3 40 C
74 Nagaraj 52 M 58 1.59 22.94213 0.9 94.33402 90/60 12.6 - 59 N
75 Nagendran 59 M 53 1.54 22.34778 4.1 15.98002 136/80 7.7 _ 57 N
76 Narasimhan 53 M 54 1.58 21.63115 0.8 107.6512 98/70 12.7 - 58 N
77 Naseema 56 F 41 1.57 16.63353 0.7 92.14918 126/78 11.3 - 65 N
78 Natarajan 41 M 54 1.62 20.57613 8.4 7.519681 156/96 7.9 2 56 C
79 Noor Jahan 59 F 55 1.6 21.48438 0.8 78.15701 150/90 11.6 - 51 N
80 Palaniappan 54 M 43 1.49 19.3685 2.9 24.26217 110/78 8.3 1.2 53 C
81 Palanivel 59 M 45 1.53 19.22338 5.1 12.42207 100/68 7.4 2 52 C
82 Pandiyan 68 M 72 1.54 30.35925 6.8 8.659609 150/100 8.2 2 52 C
83 Parthi Sarathi 68 M 49 1.59 19.38214 6.5 9.122451 110/74 6.6 2.2 59 N
84 Periyasamy 68 M 57 1.59 22.54658 1.7 42.88205 120/80 8 _ 64 N
85 Peryakarupusamy 65 M 42 1.49 18.91807 7.6 7.686569 150/100 6 2.2 53 N
86 Petchiammal 38 F 45 1.56 18.49112 0.6 119.1061 140/100 11.8 - 56 C
87 Prabhu 57 M 49 1.56 20.13478 5.6 11.22952 110/72 7.6 _ 54 N
88 Prema 63 F 45 1.59 17.79993 3.6 13.59495 116/78 7.8 2 57 N
89 Premkumar 58 M 62 1.6 24.21875 0.9 92.26588 156/94 13.8 - 58 N
90 Pushpavalli 70 F 50 1.48 22.82688 7 6.177585 160/90 7.8 2 41 C
91 Raghavan 52 M 64 1.57 25.96454 0.9 94.33402 150/100 15 - 51 C
92 Raj Kumar 52 M 47 1.54 19.81784 3.3 21.06197 120/80 6.4 1.3 58 N
93 Rajappan 69 M 45 1.53 19.22338 15.6 3.311774 160/90 3.9 2.4 58 N
94 Rajasekhar 52 M 58 1.56 23.833 0.8 108.0683 150/100 14.6 - 54 C
95 Rajaselvam 63 M 48 1.53 20.50493 0.7 89.97202 148/100 12 0.7 53 C
96 Rajendran 35 M 47 1.56 19.31295 14.5 4.135694 180/100 8.5 2.2 48 C
97 Rajvel 68 M 54 1.61 20.83253 2 35.5488 130/80 8.3 0.9 53 N
98 Ramachandran 43 M 56 1.48 25.56611 2.2 34.95127 110/70 9.6 _ 51 C
99 Ramar 43 M 50 1.64 18.59012 4.3 16.12858 96/72 7.9 _ 54 C
100 Ramasamy 45 M 54 1.62 20.57613 5.7 11.54333 140/94 7.3 1.7 53 N
101 Ramasamy 47 M 54 1.56 22.18935 1 85.26622 124/80 13.5 - 56 N
102 Ramkrishna 60 M 51 1.58 20.42942 5.8 10.67216 132/78 7.1 2.1 54 N
103 Raniammal 48 F 65 1.53 27.7671 4.2 12.02528 90/60 9.5 2.1 55 N
104 Rathinam 34 M 53 1.57 21.50189 1.5 57.03131 160/100 9 0.7 58 C
105 Rathinam 36 M 54 1.59 21.35991 1 90.00848 170/100 14 - 57 C
106 Ravichandran 55 M 45 1.58 18.02596 7.8 7.716886 160/100 4.5 2.1 42 C
107 Remadevi 66 F 65 1.55 27.05515 0.8 76.39827 160/96 12.5 0.8 54 N
108 Ronald 51 M 65 1.63 24.4646 0.9 94.7066 148/96 13.4 - 51 N
109 Santhanalakshmi 69 F 55 1.52 23.8054 4.3 10.87196 156/98 10.1 _ 56 C
110 Santhanamal 67 F 50 1.53 21.35931 4.1 11.55503 170/110 9.5 _ 42 C
111 Saral salima 38 F 48 1.56 19.72387 3.6 15.06425 180/100 8 1.4 54 C
112 Saraswathi 46 F 53 1.53 22.64086 5 9.918946 150/96 8.8 1.8 59 C
113 Saratha 54 F 56 1.47 25.91513 11.5 3.67194 180/110 6.2 2.3 54 C
114 Sathyammal 54 F 46 1.58 18.42653 0.7 92.832 120/80 12.4 - 64 N
115 Savithri 45 F 59 1.5 26.22222 1.3 47.15459 160/96 9.4 0.8 56 C
116 Selvaratinam 58 M 56 1.56 23.01118 0.9 92.26588 100/60 13.5 - 62 N
117 Sethu 63 M 56 1.59 22.15102 11.7 4.701758 160/110 5.5 2.1 47 C
118 Sethumathy 48 F 56 1.47 25.91513 0.6 113.5895 160/100 12.6 - 60 C
119 Sethupathy 66 F 48 1.5 21.33333 5.1 9.009763 170/100 8.1 2 55 C
120 Sethuraman 65 M 54 1.59 21.35991 2.5 27.7312 170/100 9.7 1.2 24 C
121 Shahul Hameed 63 M 51 1.55 21.22789 4.6 13.80779 128/86 7.7 _ 55 N
122 Shamsath Beegum 66 F 42 1.6 16.40625 5.9 7.615284 100/60 8.9 _ 60 N
123 Shankar 66 M 57 1.48 26.02264 4 16.07194 110/70 9.2 _ 57 N
124 Shanmugasundaram 37 M 55 1.56 22.60026 0.8 115.7983 100/70 12.6 - 60 N
125 Sindhuja 64 F 53 1.48 24.19649 4 12.0001 110/70 6.4 2 45 C
126 Sivan 63 M 75 1.6 29.29688 1 80.34276 150/98 12.8 - 53 N
127 Sounderapandy 58 M 57 1.58 22.83288 0.9 92.26588 100/70 12.4 - 54 N
128 Srinivasan 63 M 60 1.6 23.4375 3.1 21.77285 126/78 7.8 _ 43 C
129 Stalin Raja 50 M 54 1.57 21.90758 2.8 25.66265 138/82 8.5 1.3 48 C
130 Subadra 68 F 46 1.59 18.19548 5 9.162333 90/70 8 2.2 64 N
131 Subbiah 62 M 58 1.56 23.833 4.7 13.51314 134/78 8.6 0.8 57 N
132 Subramani 41 M 60 1.64 22.30815 5.8 11.5298 120/86 7.4 1.8 53 C
133 Sujatha 49 F 56 1.52 24.23823 1.5 39.29141 100/70 8.2 0.8 56 N
134 Sumithra 62 F 48 1.58 19.22769 0.7 90.26473 100/60 10.6 0.9 54 N
135 Sundaram 56 M 63 1.6 24.60938 12.4 4.503209 180/100 4.8 2.1 44 C
136 Tamilnila 46 F 38 1.49 17.11635 0.7 95.90335 110/70 11.6 - 56 N
137 Tamilselvi 61 F 54 1.4 27.55102 4.3 11.14736 126/86 6 2.1 54 C
138 Thirunesan 42 M 41 1.6 16.01563 4.2 16.65189 158/98 8.6 1.4 51 C
139 Umma 38 F 42 1.46 19.70351 2.1 28.05948 130/80 6.2 1.1 46 C
140 Vallarmathi 59 F 43 1.49 19.3685 6.2 7.357221 110/70 6.4 2.3 54 N
141 Veerajeeyan 63 M 65 1.57 26.37024 2.2 32.34379 148/98 10.1 0.9 63 N
142 Veerammal 54 F 54 1.49 24.32323 3.2 16.06933 106/86 5.1 1.4 52 N
143 Veerammal 45 F 46 1.57 18.66201 0.7 96.3322 150/94 12.4 - 63 N
144 Velu 52 M 59 1.56 24.24392 3.3 21.06197 160/96 9.4 1.3 60 N
145 Venkateshwar 36 M 40 1.58 16.02307 4.6 15.46895 190/110 6.3 1.3 42 C
146 Vigneshwaran 60 M 52 1.62 19.81405 0.8 104.9741 120/80 13.2 - 56 N
147 Vijayalakshmi 45 F 49 1.54 20.66116 4.9 10.19831 120/80 6.9 2.1 45 C
148 Vijayan 55 M 58 1.59 22.94213 5.2 12.32115 140/90 7.9 1.5 51 C
149 Vishnupriya 37 F 40 1.5 17.77778 0.7 100.2371 120/80 12.6 - 54 N
150 Williams 60 M 62 1.57 25.15315 12.7 4.31975 190/100 4 2.2 58 C
KEY TO MASTER CHART
M- Males
F-Females
BMI- body mass index
eGFR- estimated glomerular filtration rate
DD- diastolic dysfunction
LVEF- left ventricular ejection fraction
Hb- Hemoglobin
BP- Blood pressure
LVH- Left ventricular hypertrophy
N- Normal
C- Concentric LVH                                             

